HIV–Associated Lipodystrophy: Pathogenesis, Prognosis, Treatment, and ControversiesKoutkia, Polyxeni; Grinspoon, Steven · Annual Review of Medicine · 2004

Human immunodeficiency virus (HIV)-associated lipodystrophy and difficult intubationG. J. Mar; J. Durbridge · 2009

Adipokines in the HIV/HAART-associated lipodystrophy syndromeParuthi, Jason; Gill, Natasha; Mantzoros, Christos S. · Metabolism · 2013

HIV-Therapy Associated Lipodystrophy: Experimental and Clinical Evidence for the Pathogenesis and TreatmentStankov, M.; Behrens, G. · Endocrine‚ Metabolic & Immune Disorders-Drug Targets · 2007

A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated LipodystrophyDeshpande, Alka; Toshniwal, Harsh; Joshi, Shashank; Jani, Rajendrakumar H.; De Socio, Giuseppe Vittorio · PLOS ONE · 2016

Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular StudyDomingo, Pere; Gutierrez, María del Mar; Gallego-Escuredo, José Miguel; Torres, Ferran; Mateo, Gracia María; Villarroya, Joan; de los Santos, Ignacio; Domingo, Joan Carles; Villarroya, Francesc; Rio, Luis Del; Estrada, Vicente; Giralt, Marta; Landay, Alan · PLoS ONE · 2014

Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapyA Winston; J Amin; PWG Mallon; D Marriott; A Carr; DA Cooper; S Emery · 2006

Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapyA Calmy; D Carey; PWG Mallon; H Wand; M Law; DA Cooper; A Carr; on behalf of the INITIO Trial International Co-ordinating Committee; HAMA study coordination team · 2008